Diagnosis of ascites in infants and children by history, examination and investigations

Ascites

Diagnosis of Ascites in Infants and Children

Diagnosis of ascites in infants and children fromega age of 1month to 18 year

Asmaa abo bakr Ahmed

Doctor

Assiut University

Liver Cirrhosis

Intrahepatic reinfusion in cirrhotic patients

autologous highly purified CD133+ stem cells (SCs)

Azienda Ospedaliera-Universitaria, Policlinico S. Orsola-Malpighi,

Azienda Ospedaliera-Universitaria, Policlinico S. Orsola-Malpighi

Intrahepatic Reinfusion of CD133+ Stem Cells in Cirrhotic Patients

Phase 1 Study of Intrahepatic Reinfusion of Highly Purified CD133+ Stem Cells in Patients With End-Stage Liver Disease

Roberto M. Lemoli, MD

University of Bologna

Esophageal Varices

Portal Hypertension

Gastric Varices

A Prospective Evaluation of Computerized Tomographic(CT) Scanning as a Screening Modality for Esophageal Varices

The Accuracy of Contrast Abdominal CT for the Detection of High-Grade Esophageal and Gastric Varices in Patients With Cirrhosis

Patrick S. Kamath

Mayo Clinic

40 micrograms/kg every other day (QOD) x 3 every 4 weeks in patients with chronic lymphocytic leukemia, the most prevalent form of adult leukemia.

LMB-2 in Chronic Lymphocytic Leukemia

Sex: Female, Male

Ethnicity (NIH/OMB)

Race (NIH/OMB)

Region of Enrollment

Response is measured by the 1996 National Cancer Institute (NCI) Working Group Criteria (NCIWG). Complete response is defined as no hepatomegaly, splenomegaly, or lymphadenopathy by physical examination and appropriate radiographic techniques. Lymph nodes must resolve to <1.0cm of 1-1.5cm at baseline, or <1.5cm if >1.5cm at baseline. Partial response is >=50% decrease in peripheral blood lymphocytes count from the pretreatment baseline value. Progressive disease is >=50% increase in the sum of the products of the greatest perpendicular dimensions of a t least 2 lymph nodes on two consecutive examinations 2 weeks apart (at least 1 node must be >=2cm) or appearance of new palpable lymph nodes. Stable disease is characterized by not meeting the above criteria. For additional details about the NCIWG, see the protocol link module.

Response Rate

Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module.

Number of Participants With Adverse Events

Overall Study

Robert J. Kreitman, M.D.

Leukemia

Lymphocytic

Chronic

40 micrograms/kg every other day (QOD) x 3 every 4 weeks

LMB-2

National Institutes of Health Clinical Center, 9000 Rockville Pike

Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia

A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for Treatment of CD25 Positive Chronic Lymphocytic Leukemia

splenomegaly/albumina

Diagnosis of Ascites in Infants and Children

Intrahepatic Reinfusion of CD133+ Stem Cells in Cirrhotic Patients

A Prospective Evaluation of Computerized Tomographic(CT) Scanning as a Screening Modality for Esophageal Varices

Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia

Il database di erbe medicinali più completo supportato dalla scienza